Pamiparib
- Generic Name
- Pamiparib
- Drug Type
- Small Molecule
- Chemical Formula
- C16H15FN4O
- CAS Number
- 1446261-44-4
- Unique Ingredient Identifier
- 8375F9S90C
- Background
Pamiparib is under investigation in clinical trial NCT03933761 (Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy).
- Indication
用于既往经过二线及以上化疗的伴有胚系BRCA(gBRCA)突变的复发性晚期卵巢癌、输卵管癌或原发性腹膜癌患者的治疗。
Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer
- Conditions
- Ovarian Cancer
- Interventions
- Drug: Placebo capsule
- First Posted Date
- 2018-05-08
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 224
- Registration Number
- NCT03519230
- Locations
- 🇨🇳
The First Hospital of Jilin University, Changchun, Jilin, China
🇨🇳Southwest Hospital, Chongqing, Chongqing, China
🇨🇳Chongqing Cancer Hospital, Chongqing, Chongqing, China
Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer
- Conditions
- Advanced or Inoperable Gastric Cancer
- Interventions
- Drug: Placebo
- First Posted Date
- 2018-02-09
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 136
- Registration Number
- NCT03427814
- Locations
- 🇺🇸
Scri Florida Cancer Specialist East, West Palm Beach, Florida, United States
🇺🇸Goshen Center For Cancer Care, Goshen, Indiana, United States
🇺🇸Novant Health Hematology Charlotte, Charlotte, North Carolina, United States
Study of the Efficacy, Safety and Pharmacokinetics of Pamiparib (BGB-290) in Participants With Advanced Solid Tumors
- Conditions
- Advanced High-grade Ovarian CancerTriple Negative Breast Cancer
- Interventions
- First Posted Date
- 2017-11-07
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 128
- Registration Number
- NCT03333915
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Henan Cancer Hospital, Zhengzhou, Henan, China
Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors
- Conditions
- Locally Advanced or Metastatic Solid Tumors
- Interventions
- First Posted Date
- 2017-05-12
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 139
- Registration Number
- NCT03150810
- Locations
- 🇺🇸
Start Midwest, Grand Rapids, Michigan, United States
🇺🇸Washington University in St Louis, Saint Louis, Missouri, United States
🇺🇸Montefiore Medical Park At Eastchester Einstein Campus, Bronx, New York, United States
A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Participants With Newly Diagnosed or Recurrent Glioblastoma
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- First Posted Date
- 2017-05-12
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- BeiGene USA, Inc.
- Target Recruit Count
- 116
- Registration Number
- NCT03150862
- Locations
- 🇺🇸
Center For Neurosciences, Tucson, Arizona, United States
🇺🇸UCLA, Los Angeles, California, United States
🇳🇱Universitair Medisch Centrum Utrecht, Utrecht, Netherlands
The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors
- First Posted Date
- 2016-01-21
- Last Posted Date
- 2021-12-06
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 229
- Registration Number
- NCT02660034
- Locations
- 🇦🇺
Prince of Wales, Randwick, New South Wales, Australia
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
🇬🇧Sarah Cannon Research Institute, London, United Kingdom
Phase 1a/1b BGB-290 for Advanced Solid Tumors.
- Conditions
- For Participants With Advanced Solid Tumors Failed With Previous Lines of Treatment
- Interventions
- First Posted Date
- 2015-02-12
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 101
- Registration Number
- NCT02361723
- Locations
- 🇦🇺
Cancer Care Wollongong, Wollongong, New South Wales, Australia
🇦🇺Gosford Hospital, Gosford, New South Wales, Australia
🇦🇺Flinders Medical Centre, Bedford PK, South Australia, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.